Proof of Concept / Clinical PK Tool
Bayesian Vancomycin
PK Calculator
An advanced pharmacokinetic calculator implementing Bayesian Maximum A Posteriori (MAP) estimation for individualized vancomycin dosing. Supports multiple validated population PK models, AUC-guided dosing per ASHP/IDSA 2020 consensus guidelines, and real-time concentration-time profiling.
Clinical Disclaimer: This tool is a proof-of-concept for portfolio demonstration purposes only. It is NOT validated for clinical use and should NOT be used for patient care decisions. All pharmacokinetic models are approximations of published parameters. Clinical vancomycin dosing should be performed using validated, institution-approved software and verified by a licensed pharmacist.
Patient Demographics
Population PK Model
Dosing & Targets
Current Dosing
Targets
Observed Drug Levels (Bayesian Updating)
Enter measured vancomycin serum levels to refine PK estimates via Bayesian MAP estimation. The algorithm updates population priors with patient-specific data to generate individualized parameters.
No observed levels entered
Add drug levels to enable Bayesian parameter estimation
Estimated PK Parameters
Concentration-Time Profile
Concentration-Time Profile (72 hr)
Blue line: predicted concentration curve | Red dots: observed levels | Green band: target trough range
Dose Recommendations
| Dose (mg) | Interval | Pred Peak | Pred Trough | AUC₂₄/MIC | Rationale |
|---|---|---|---|---|---|
1750Recommended | q12h | 40.9 mg/L | 8.1 mg/L | 487 | AUC₂₄/MIC 487 within target 400-600 |
1250 | q8h | 35.8 mg/L | 12.4 mg/L | 522 | AUC₂₄/MIC 522 within target 400-600 |
2000 | q12h | 46.7 mg/L | 9.3 mg/L | 557 | AUC₂₄/MIC 557 within target 400-600 |
1000 | q8h | 28.7 mg/L | 9.9 mg/L | 418 | AUC₂₄/MIC 418 within target 400-600 |
1500 | q12h | 35.1 mg/L | 7.0 mg/L | 418 | AUC₂₄/MIC 418 within target 400-600 |
Technical Architecture
Bayesian MAP
Grid-search optimization minimizing the MAP objective function with log-normal priors. Two-phase approach: coarse grid (30×20) followed by fine refinement (20×20) around the optimum.
PK Engine
One-compartment IV infusion model with multi-dose superposition. Steady-state peak/trough via accumulation factor. AUC₂₄ calculated both analytically (Dose₂₄/CL) and via trapezoidal integration.
Population Models
Five validated models spanning 1984-2018: Matzke, Bauer, Thomson, Crass, and Empiric Trough. Each provides population priors for CL and Vd with inter-individual variability (BSV) estimates.
References
- Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: ASHP/IDSA/SIDP 2020 Update. Am J Health-Syst Pharm. 2020;77(11):835-864.
- Crass RL, et al. Renal dosing of vancomycin. Clin Infect Dis. 2020;71(6):1560-1567.
- Thomson AH, et al. Development and evaluation of vancomycin dosage guidelines. J Antimicrob Chemother. 2009;63(5):1050-1057.
- Bauer LA. Applied Clinical Pharmacokinetics. 2nd ed. McGraw-Hill; 2008.
- Matzke GR, et al. Clinical pharmacokinetics of vancomycin. Antimicrob Agents Chemother. 1984;25(4):433-437.